This Week in Urology — Jun 19, 2026

Welcome to This Week in Urology. This week we're covering 9 notable papers spanning advances in urologic oncology, new approaches in functional urology, and key updates in pediatric care and surgical technique. Let's dive in.

First, in urologic oncology, a key editorial in European Urology reinforces the current standard of care for muscle-invasive bladder cancer [1]. Despite impressive pathological complete response rates seen with newer neoadjuvant regimens, the authors argue that consolidative radical cystectomy remains essential. The survival benefits in recent trials were built upon high rates of surgery, and current clinical restaging tools are simply not reliable enough, agreeing with true pathological response only about half the time. Trials of bladder preservation using systemic therapy alone have shown concerning rates of recurrence, and while trimodal therapy with radiation is promising, it remains investigational. The take-home message is that until we have validated biomarkers and prospective trial data to the contrary, cystectomy should remain the cornerstone of curative-intent treatment. Shifting to upper tract urothelial carcinoma in a specific high-risk population, a study in the World Journal of Urology examined outcomes in kidney transplant recipients [9]. This retrospective analysis found that performing a bilateral native radical nephroureterectomy provided significant survival advantages over a unilateral procedure, with better overall, cancer-specific, disease-free, and progression-free survival. Interestingly, when the authors performed a propensity-score matched comparison between transplant patients who received a unilateral nephroureterectomy and non-transplant patients receiving the same surgery, their long-term survival outcomes were comparable. This suggests that with appropriate surgical selection and surveillance, the prognosis for these transplant patients can be similar to that of the general population. And in prostate cancer, the World Journal of Urology also published a first look at single-port robotic radical prostatectomy from a center in the United Kingdom [7]. Reporting on their initial 50 cases, the authors found the procedure to be safe and feasible. The median operative time was 120 minutes, with a median blood loss of 100 milliliters and a median hospital stay of just one day. At three months, 68 percent of patients were fully continent, and 75 percent achieved erectile function sufficient for intercourse with medical support. These early results are comparable to published international data and support the need for larger studies comparing the single-port platform against traditional multi-port robotics.

Turning to functional urology and technology, we have two papers on incontinence and a broader look at artificial intelligence. First, a study in Neurourology and Urodynamics offers a potentially practice-changing update for intravesical botulinum toxin injections for overactive bladder [8]. In a retrospective cohort study of 133 patients, investigators compared the traditional 20-injection, trigone-sparing template to a novel 10-injection template that includes two sites in the trigone. The results significantly favored the new, simpler approach. Patients receiving the 10-point injection had a much higher overall symptom improvement for urinary urgency, frequency, and especially incontinence—with a 95 percent response rate for incontinence compared to just 62 percent in the traditional group. Importantly, there was no significant difference in adverse events, suggesting the novel template is not only more effective but also safe and more practical. Also in Neurourology and Urodynamics, a pilot study introduces an innovative device for refractory urinary incontinence [5]. Thirteen women were implanted with an adaptive pudendal nerve stimulator, which delivers a basal 15 Hertz stimulation that can be temporarily boosted to 40 Hertz by the patient simply tapping over the device. The study found the system to be safe and technically feasible. At six months, mean daily incontinence episodes dropped from 5.7 to 1.8. Eight of the thirteen patients were considered responders with over 50 percent improvement, and five regained full continence. Urodynamics confirmed that the adaptive stimulation provided an additional increase in cystometric capacity beyond the basal stimulation, validating the device's mechanism. Broadening the lens on technology, a review in BJU International characterized all United States Food and Drug Administration-cleared artificial intelligence devices in urology [4]. The analysis found that of nearly 1400 AI devices cleared by the FDA, only 30 are specific to urology. The majority are for radiology, with prostate imaging being the most common application. A critical finding was the frequent lack of publicly available evidence supporting their authorization. Information on study design and validation was often missing, and patient demographics were poorly reported. In the few instances where race was documented, over 86 percent of subjects in the training and validation cohorts were White. This highlights a need for greater transparency and post-authorization evaluation to ensure these tools are safe and effective across diverse patient populations.

Finally, we'll cover important findings in pediatric urology and a practical point on BPH surgery. A large study in The Journal of Urology used the National Surgical Quality Improvement Program-Pediatrics database to assess anesthesia risk in nearly 146,000 children undergoing elective outpatient surgery [2]. The analysis revealed that age is a critical factor, with a clear inflection point at six months. Compared to infants younger than six months, children aged six to eleven months had 76 percent lower odds of respiratory failure requiring reintubation and other serious adverse events. The overall event rates were very low, but the findings strongly suggest that children under six months warrant heightened perioperative vigilance. A second paper in The Journal of Urology reviewed a decade of pediatric renal trauma data from the National Trauma Databank [3]. The analysis of over 15,000 patients showed that 90 percent were managed non-operatively, consistent with modern practice. However, unlike in adult trauma, the rate of nephrectomy, at around 6 percent, did not decrease over the 10-year study period. For high-grade injuries that required intervention for bleeding, angioembolization appeared to achieve a higher rate of kidney salvage compared to surgical repair, though the authors caution that selection bias may influence this finding. Lastly, for surgeons performing Holmium laser enucleation of the prostate, a systematic review and meta-analysis in the Journal of Endourology compared the performance of commonly used morcellator devices [6]. After analyzing 34 studies including over 7,000 patients, the researchers found no statistically significant differences between systems like the Wolf Piranha, VersaCut, and others. Morcellation time, efficiency, catheterization duration, and rates of complications like bladder injury or device malfunction were all comparable. The conclusion is that the choice of morcellator can be guided by surgeon preference, cost, and availability rather than inherent performance differences.

If you only have time for one paper this week, make it the cohort study in Neurourology and Urodynamics on a novel botulinum toxin injection template [8]. This study suggests a 10-point template including the trigone is more effective than the traditional 20-point method for overactive bladder, potentially simplifying the procedure and improving outcomes without increasing risk.

Here are the key takeaways from this week in Urology: First, for muscle-invasive bladder cancer, consolidative radical cystectomy remains the standard of care after neoadjuvant therapy; current restaging tools are not reliable enough for a bladder preservation strategy [1]. Second, in treating refractory overactive bladder, a simplified 10-point botulinum toxin injection template that includes the trigone appears more effective than the traditional 20-point, trigone-sparing method, with a similar safety profile [8]. Third, for elective outpatient surgery in children, be aware that infants under 6 months of age have a significantly higher risk of postoperative respiratory failure and serious adverse events, warranting heightened perioperative vigilance [2]. Fourth, in kidney transplant recipients with upper tract urothelial carcinoma, bilateral native nephroureterectomy provides a significant survival advantage over a unilateral approach [9]. And finally, despite the growing number of FDA-cleared AI tools in urology, clinicians should be cautious, as the evidence supporting their approval often lacks transparency and is based on training data with limited demographic diversity [4].

That's your roundup for This Week in Urology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.

If this weekly briefing is useful, follow the show in your podcast app so new episodes arrive automatically. And for audio briefings on your own clinical questions and papers, visit audioscholar dot C C.

This is an automated summary generated by artificial intelligence, which can make mistakes. Always review the original source materials.